J&J Appeals Risperdal Lawsuit Verdict Reached in 2012 over Antipsychotic Drug Marketing
An Arkansas Supreme Court judge is scheduled to hear oral arguments from Johnson & Johnson next month in the company’s efforts to overturn a Risperdal lawsuit verdict reached in 2012 over its anti-psychotic drug and two other medications.
According to The Associated Press, a court hearing is slated for February 27th in Little Rock, a near-two years after a judge in Pulaski County ordered Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc. to pay $1.2 billion in charges related to their promotions of three separate medications including Risperdal, in which they were found to have downplayed and even concealed side effect information.
For each of 240,000 Risperdal prescriptions paid for by the state Medicaid program over a 3.5 year period, the two companies were fined $5,000, according to the ruling, which responded to claims originally brought by Attorney General Dustin McDaniel.
Next month’s oral arguments will follow a significant settlement from Johnson & Johnson over the marketing of Risperdal and other medications. In November 2013, the company agreed to pay more than $2.5 billion in fines to the U.S. Department of Justice, who charged the company for promoting Risperdal for uses not approved by the FDA. Elderly patients with dementia and children were among the groups who had been prescribed the medication off-label, despite the fact that it was not approved for pediatric uses until 2006.
Hundreds of Risperdal Gynecomastia Lawsuits Filed in Pennsylvania Litigation
Johnson & Johnson and Janssen are also facing hundreds of Risperdal lawsuits alleging male gynecomastia, a condition categorized by male breast growth, and other side effects. According to recent records, a total of 275 cases are currently pending in the Philadelphia Court of Common Pleas in Pennsylvania after being filed on behalf of men and young boys who may have experienced this complication after long-term use of Risperdal. According to Risperdal gynecomastia lawsuits, doctors and patients were not properly made aware of risks associated with the medication by Johnson & Johnson and Janssen. Risperdal is approved by the FDA to treat bipolar disorder and schizophrenia, and is also frequently prescribed to treat irritability in children with autism.
Contact an Attorney for More about Risperdal Lawsuits
If you or a man you love experienced Risperdal gynecomastia complications, call a lawyer at Bernstein Liebhard LLP to find out if you are eligible to file a claim alleging gynecomastia. The Firm can be reached at (877) 779-1414.